This analysis identifies metabolic dysfunction signatures affecting prognosis in prostate cancer, suggesting new targets for treatment.
This study defines a prevalent metabolic dysfunction signature in PCa that is integrally linked to patient prognosis, genomic instability, therapeutic resistance, and the establishment of an immunosuppressive tumor microenvironment. Furthermore, HPRT1 is functionally validated as a promoter of PCa progression and is positioned as a novel potential biomarker and therapeutic target for both intervention and prognosis assessment.
No takes yet. Share an insight, caveat, or question.
Nie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: